Elasmogen and Intract Enter License Agreement for Soteria® and Phloral® Technologies | 16.09.2022

Date: 16th September 2022 Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced a global license agreement that gives Elasmogen exclusive access to Soteria® and Phloral® technologies for oral colonic delivery of therapeutic proteins, deriving from Elasmogen’s soloMER™ platform, for an undisclosed target for treatment of Crohn’s disease and ulcerative […]

Research Scientist/Senior Research Scientist – Protein engineer and Protein chemist in Antibody drug discovery | 15.08.2022

Description Elasmogen Ltd is a multi-award-winning next generation therapeutic biologics company discovering and developing soloMERs™ for the treatment of oncology and autoimmune mediated inflammatory diseases. Currently located on the Foresterhill Health Campus, Aberdeen, and part of the city’s thriving biologics cluster, Elasmogen will be moving into the £40 million state-of-the-art Aberdeen life sciences BioHub also […]

BGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company Elasmogen | 18.05.2022

Aberdeen, Scotland, 18 May 2022: Elasmogen – a biopharmaceutical company discovering and developing new therapeutics using its unique soloMERTM platform – has secured £8 million investment. The funding round was led by BGF and Scottish National Investment Bank (The Bank), with additional support from existing investor Scottish Enterprise. The multi-million-pound investment will enable Aberdeen-based Elasmogen […]